Latest medicines approvals announced in Scotland and Wales

Latest medicines approvals announced in Scotland and Wales

June 22 2016 The All Wales Medicines Strategy Group has announced two new recommendations for...

Which? challenges dietary supplements claims around reducing dementia risk

Which? challenges dietary supplements claims around reducing dementia risk

June 20 2016 Consumers’ association Which? has challenged dietary supplement products which...

High dose loperamide linked with serious heart problems

High dose loperamide linked with serious heart problems

June 20 2016 A warning advising of a risk of severe cardiac problems associated with people...

CAM users less likely to start chemotherapy for breast cancer

CAM users less likely to start chemotherapy for breast cancer

May 18 2016 Women with breast cancer are less likely to start chemotherapy when using certain...

VMS may need to include iron and folic acid to help reduce some birth risks

VMS may need to include iron and folic acid to help reduce some birth risks

May 11 2016 Vitamin and mineral supplements (VMS) taken before a woman becomes pregnant or during...

  • Latest medicines approvals announced in Scotland and Wales

    Latest medicines approvals announced in Scotland and Wales

    Wednesday, 22 June 2016 14:31
  • Which? challenges dietary supplements claims around reducing dementia risk

    Which? challenges dietary supplements claims around reducing dementia risk

    Tuesday, 21 June 2016 13:23
  • High dose loperamide linked with serious heart problems

    High dose loperamide linked with serious heart problems

    Tuesday, 21 June 2016 11:45
  • CAM users less likely to start chemotherapy for breast cancer

    CAM users less likely to start chemotherapy for breast cancer

    Wednesday, 18 May 2016 14:50
  • VMS may need to include iron and folic acid to help reduce some birth risks

    VMS may need to include iron and folic acid to help reduce some birth risks

    Wednesday, 11 May 2016 13:46

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

ApprovalJune 22 2016

The All Wales Medicines Strategy Group has announced two new recommendations for medicines by the NHS in Wales. The Scottish Medicines Consortium has recommended four medicines for use, but has also advised against two others.

The AWSMG recommendations are:

  • pasireotide (Signifor) for treating adults with acromegaly when surgery is not an option or has not been curative and when other somatostatin analogues are not adequately controlling the condition;
  • dulaglutide (Trulicity) for restricted use in type 2 diabetes in adults to improve glycaemic control where there has been a failure, intolerance or a contraindication to standard triple therapy (metformin and two other antidiabetic medicines) as an alternative to insulin therapy. It can also be used in combination with other glucose-lowering medicinal products but not insulin, when these, together with diet and exercise, have not provided adequate glycaemic control.

In Scotland, the SMC approvals are for:

  • co-careldopa (Duodopa) for advanced Parkinson’s disease and administered as a gel directly into the small intesting via a pump and tubing surgically inserted into the gut;
  • mepolizumab (Nucala) for severe eosinophilic asthma
  • blinatumomab (Blincyto) for acute lymphoblastic leukaemia
  • febuxostat (Adenuric) for patients at risk of Tumour Lysis Syndrome (TLS), a complication due to the breakdown of cancer cells leading to a rise in uric acid level in the blood which can then cause kidney damage

The Committee was unable to accept cabazitaxel (Jevtana) for advanced prostate cancer and evolocumab (Repatha) for high cholesterol.

Asthma UK has welcomed the SMC decision on mepolizumab, but remains concerned that NICE is proposing not to recommend the drug for use in England. Dr Samantha Walker, Asthma UK's Director of Research and Policy, said:

“Whilst Asthma UK has worked very hard to make sure that use of this crucial treatment for people with severe asthma was accepted in Scotland, which we are delighted to see, we have grave concerns over the difference in the situation in England.

“Mepolizumab has been shown to be clinically effective at reducing severe asthma symptoms in people with a certain type of asthma and should be available to those people who are most likely to benefit from it. Obviously this needs to be at a price that the NHS can afford, so it is essential that NICE and the manufacturer continue to work together and find a solution.”

Links:

AWSMG decisions

SMC announcement

Asthma UK comment

OTC News

June 29 2016 The NHS should support clinical pharmacist roles in community pharmacies as well as at GP practices, the New NHS Alliance has proposed.
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...